Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • quinlana
    Senior Member
    • Sep 2008
    • 119

    CNV detection via BAM depth-of-coverage

    Hello all,
    I am looking for a reliable, published tool for CNV discovery by differences in depth of coverage (DOC). Preferably something that accepts BAM as input. Our SV tool / pipeline (Hydra) works well for discovering breakpoints via paired-end mapping, but we (and others) find that certain classes of rearrangements are not easily detected by PEM yet are by DOC. In a previous study (Quinlan et al, 2010), we used an HMM on GC-corrected sliding windows, but would prefer to use a published method for a current study.

    Could someone help me out with suggestions?

    Best,
    Aaron
  • henry.wood
    Member
    • Apr 2010
    • 63

    #2
    Hello
    Have you tried CNV-seq http://tiger.dbs.nus.edu.sg/CNV-seq/
    I had a play around with it a while back. It seems easy enough to use, but you might have to convert the BAM data beforehand. It doesn't really work well with the complex changes you see in tumours, so I had to develop my own method (far too messy to share at the moment), but is good for discreet changes in constitutional DNA.
    I also tried segseq http://www.broadinstitute.org/cgi-bi...w&paper_id=182 but I couldn't get it to work. Probably more a reflection on me than the program.

    Comment

    • krobison
      Senior Member
      • Nov 2007
      • 734

      #3
      Which of the listed programs in the Wiki might fit your need? Or which have you tried & found lacking?

      Comment

      • zlu
        Member
        • Nov 2008
        • 34

        #4
        Originally posted by henry.wood View Post
        Hello
        Have you tried CNV-seq http://tiger.dbs.nus.edu.sg/CNV-seq/
        I had a play around with it a while back. It seems easy enough to use, but you might have to convert the BAM data beforehand.
        I'm trying to use CNV-seq on the bam files I created with BWA and this may be really obvious but how do you decide which is ref and which is test. If I have 2 bam files generated by mapping Illumina reads from 2 individuals against the NCBI reference genome, does it mean either one can be ref or test? I have also been playing around with the p-value and the bigger-window parameters but I get either no CNV or more than 10k CNVs in a single chromosomes. Any suggestion on the tweaking the parameters? Thank you.

        Comment

        • henry.wood
          Member
          • Apr 2010
          • 63

          #5
          Choosing which is normal depends what you are doing. If you are looking at a diseased and healthy person then it is easy. If you are looking at variation between two ordinary people then you might want to get hold of a third person, so any changes you seen can be validated. I'm led to believe that there is an artificial sequence read generator somewhere in samtools. Or you could use one of the published genomes. Then you will know whether the gain you see in person A is actually a loss in person B.
          I didn't play around too much with the parameters. Nothing to do with the ease of using the program, which was very good, it's just that cnv-seq wasn't so useful for the tumours I was dealing with. It ignored focal amplifications within a chromosomal gain, calling it all one gain. It also didn't like homozygous deletions.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM
          • GATTACAT
            Reply to Nine Things a Sample Prep Scientist Thinks About Before Sequencing
            by GATTACAT
            Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.
            07-01-2026, 11:43 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          28 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-09-2026, 10:04 AM
          0 responses
          37 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-08-2026, 10:08 AM
          0 responses
          25 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-07-2026, 11:05 AM
          0 responses
          35 views
          0 reactions
          Last Post SEQadmin2  
          Working...